Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Norovirus (NoV) causes significant human gastroenteritis globally.
• High genetic variability of NoV limits natural immunity and vaccine efficacy.
• Current vaccine strategies aim for broad protection against diverse NoV genotypes.

Purpose of the Study:

• To evaluate the immunogenicity and cross-reactivity of different Norovirus genogroup I (GI) and GII virus-like particles (VLPs).
• To determine the optimal VLP candidates for a bivalent Norovirus vaccine.
• To assess the induction of type-specific and cross-reactive immune responses in a murine model.

Main Methods:

• Monovalent immunization of BALB/c mice with Norovirus GI.1-2001, GI.3-2002, GII.4-1999, and GII.4-2010 New Orleans VLPs.
• Measurement of type-specific and cross-reactive serum IgG antibodies.
• Assessment of blocking antibody responses against homologous and heterologous VLPs.

Main Results:

• All tested VLPs induced comparable type-specific IgG and blocking antibodies.
• Significant variation was observed in the induction of cross-reactive IgG and blocking antibodies between different VLP genotypes.
• Cross-protection between GI and GII genogroups was limited, confirming previous findings.

Conclusions:

• NoV GI.3 and GII.4-1999 VLPs demonstrated potential for inclusion in a bivalent vaccine formulation.
• These selected VLPs may induce protective immune responses across common human Norovirus genogroups.
• Further research supports the development of a bivalent Norovirus vaccine for broad-spectrum protection.